Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: a prospective randomized study.
This study was designed to determine if the efficiency of in-vitro maturation (IVM) in women with normal ovaries can be improved by gonadotrophin administration. 400 women were randomly allocated in four groups: group A, non-primed cycles; group B, human chorionic gonadotrophin (HCG)-primed cycles; group C, FSH-primed cycles; and group D, FSH- plus HCG-primed cycles. There were significant differences in the IVM rate among the groups. In groups where HCG was used, the overall maturation rate was higher (57.9% in group B and 77.4% in group D; 48.4% in group A and 50.8% in group C) and the percentage of total available metaphase II-stage oocytes was higher (60.4% in group B and 82.1% in group D; 48.4% in group A and 50.8% in group C). The overall clinical pregnancy rate per transfer (CPR) was 18.3% and the implantation rate (IR) was 10.6%. There was a difference in CPR among the groups: group D (29.9%) versus group A (15.3%), P = 0.023; group D versus group B (7.6%), P < 0.0001; group D versus group C (17.3%), P = 0.046. The results of this study are clearly in favour of FSH plus HCG priming. FSH priming and HCG priming alone showed no significant effects on clinical outcome.
Fadini
R
R
Biogenesi Reproductive Medicine Centre, Istituti Clinici Zucchi, V Zucchi, 24-Monza, Italy.
Dal Canto
M B
MB
Mignini Renzini
M
M
Brambillasca
F
F
Comi
R
R
Fumagalli
D
D
Lain
M
M
Merola
M
M
Milani
R
R
De Ponti
E
E
D000328:Adult; D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004338:Drug Combinations; D010064:Embryo Implantation / Q000187:drug effects / Q000502:physiology; D004624:Embryo Transfer; D047108:Embryonic Development / Q000187:drug effects; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage; D006062:Gonadotropins / Q000008:administration & dosage*; D006262:Health; D006801:Humans; D009865:Oocytes / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D009866:Oogenesis / Q000187:drug effects* / Q000502:physiology; D010053:Ovary / Q000187:drug effects* / Q000502:physiology; D011247:Pregnancy; D018873:Pregnancy Rate
D006063:Chorionic Gonadotropin; D004338:Drug Combinations; D005300:Fertility Agents, Female; D006062:Gonadotropins; D005640:Follicle Stimulating Hormone